Actelion's Selexipag for pulmonary arterial hypertension lowers mortality risks during Phase III study Actelion's experimental drug selexipag for the treatment of pulmonary arterial hypertension shows promising result in the phase III study GRIPHON, which involved over 1,000 PAH patients from 39 countries. by Rhodi Lee